Evidence map›Paper›PMID 19170447›Full record

ArticleBehavioral neuroscience2009

Peripheral delivery of a ROCK inhibitor improves learning and working memory.

Matthew J Huentelman, Dietrich A Stephan, Joshua Talboom, Jason J Corneveaux, David M Reiman, Jill D Gerber, Carol A Barnes, Gene E Alexander, Eric M Reiman, Heather A Bimonte-Nelson

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Behavioral neuroscience, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06362707 (A Placebo Controlled Randomized Double-blind Parallel Group 12-month Trial of Fasudil for the Treatment of Early Alzheimer's Disease), which is not on this map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06362707 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

A Placebo Controlled Randomized Double-blind Parallel Group 12-month Trial of Fasudil for the Treatment of Early Alzheimer's Disease (FEAD)

TypeinterventionalSponsorHelse Stavanger HFRan2024 to 2028Enrolled200ConditionsCognitive Decline, Mild, Alzheimer DiseaseArmsFasudil, Placebo
3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Identification ofProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  6. Rock inhibitors in Alzheimer's disease.Frontiers in aging · 2025
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Ras acts as a molecular switch between two forms of consolidated memory inProceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Matthew J HuentelmanNeurogenomics Division, The Translational Genomics Research Institute, Phoenix, Arizona 85004, USA. mhuentelman@tgen.org
Dietrich A Stephan
Joshua Talboom
Jason J Corneveaux
David M Reiman
Jill D Gerber
Carol A Barnes
Gene E Alexander
Eric M Reiman
Heather A Bimonte-Nelson
Translational Genomics Research Institute · USArizona Alzheimer’s ConsortiumAlzheimer's Association · USArizona State University · USUniversity of Arizona · US

Funding

Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI GONZALEZ HERNANDEZ, GRACIELA · 2001 to 2020
$32.5M
Genetic Variation in KIBRA and its role in Human Episodic MemoryR01NS059873 · NINDS · TRANSLATIONAL GENOMICS RESEARCH INST · PI HUENTELMAN, MATT · 2008 to 2011
$1.4M
NIA NIH HHS AG19610NIA NIH HHS P30 AG019610NINDS NIH HHS NS059873NINDS NIH HHS R01 NS059873
6 · The paper itself

Abstract

Previously, utilizing a series of genome-wide association, brain imaging, and gene expression studies we implicated the KIBRA gene and the RhoA/ROCK pathway in hippocampal-mediated human memory. Here we show that peripheral administration of the ROCK inhibitor hydroxyfasudil improves spatial learning and working memory in the rodent model. This study supports the action of ROCK on learning and memory, suggests the potential value of ROCK inhibition for the promotion of cognition in humans, and highlights the powerful potential of unbiased genome-wide association studies to inform potential novel uses for existing pharmaceuticals.

Indexed as

1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineAgingAnimalsDose-Response Relationship, DrugMaleMaze LearningMemory, Short-TermRatsRats, Inbred F344rhoA GTP-Binding Protein1-(5-Isoquinolinesulfonyl)-2-MethylpiperazinehydroxyfasudilrhoA GTP-Binding Protein

Identifiers

PMID19170447
PMCPMC2701389
OpenAlexW2140612266

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.